AXP vs. NVO: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AXP and NVO, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
AXP is a standard domestic listing, while NVO trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | AXP | NVO |
|---|---|---|
| Company Name | American Express Company | Novo Nordisk A/S |
| Country | United States | Denmark |
| GICS Sector | Financials | Health Care |
| GICS Industry | Consumer Finance | Pharmaceuticals |
| Market Capitalization | 219.76 billion USD | 244.20 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | June 1, 1972 | April 30, 1981 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of AXP and NVO by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | AXP | NVO |
|---|---|---|
| 5-Day Price Return | 3.17% | 4.72% |
| 13-Week Price Return | 9.97% | -17.05% |
| 26-Week Price Return | 1.90% | -37.87% |
| 52-Week Price Return | 27.46% | -60.23% |
| Month-to-Date Return | 5.51% | 15.71% |
| Year-to-Date Return | 6.41% | -41.70% |
| 10-Day Avg. Volume | 2.26M | 6.68M |
| 3-Month Avg. Volume | 2.68M | 6.63M |
| 3-Month Volatility | 22.00% | 65.20% |
| Beta | 1.32 | 1.52 |
Profitability
Return on Equity (TTM)
AXP
32.87%
Consumer Finance Industry
- Max
- 32.87%
- Q3
- 20.39%
- Median
- 14.14%
- Q1
- 7.64%
- Min
- -10.63%
In the upper quartile for the Consumer Finance industry, AXP’s Return on Equity of 32.87% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
NVO
77.86%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
NVO’s Return on Equity of 77.86% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
AXP
13.55%
Consumer Finance Industry
- Max
- 19.68%
- Q3
- 15.94%
- Median
- 13.37%
- Q1
- 9.73%
- Min
- 3.66%
AXP’s Net Profit Margin of 13.55% is aligned with the median group of its peers in the Consumer Finance industry. This indicates its ability to convert revenue into profit is typical for the sector.
NVO
35.61%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
NVO’s Net Profit Margin of 35.61% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
Operating Profit Margin (TTM)
AXP
17.15%
Consumer Finance Industry
- Max
- 50.11%
- Q3
- 29.38%
- Median
- 18.31%
- Q1
- 14.26%
- Min
- -5.45%
AXP’s Operating Profit Margin of 17.15% is around the midpoint for the Consumer Finance industry, indicating that its efficiency in managing core business operations is typical for the sector.
NVO
45.78%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
NVO’s Operating Profit Margin of 45.78% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
Profitability at a Glance
| Symbol | AXP | NVO |
|---|---|---|
| Return on Equity (TTM) | 32.87% | 77.86% |
| Return on Assets (TTM) | 3.62% | 24.22% |
| Net Profit Margin (TTM) | 13.55% | 35.61% |
| Operating Profit Margin (TTM) | 17.15% | 45.78% |
| Gross Profit Margin (TTM) | 61.37% | 83.95% |
Financial Strength
Current Ratio (MRQ)
AXP
0.71
Consumer Finance Industry
- Max
- 5.34
- Q3
- 4.21
- Median
- 2.67
- Q1
- 0.71
- Min
- 0.20
For the Consumer Finance industry, the Current Ratio is often not the most suitable measure of short-term liquidity.
NVO
0.78
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
AXP
6.47
Consumer Finance Industry
- Max
- 6.63
- Q3
- 3.39
- Median
- 2.21
- Q1
- 0.94
- Min
- 0.00
The Debt-to-Equity Ratio is often not the primary focus for assessing leverage in the Consumer Finance industry.
NVO
0.59
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
NVO’s Debt-to-Equity Ratio of 0.59 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
AXP
33.37
Consumer Finance Industry
- Max
- 49.63
- Q3
- 39.33
- Median
- 4.56
- Q1
- 2.97
- Min
- -15.69
The Interest Coverage Ratio is often not a primary indicator of debt servicing capacity in the Consumer Finance industry.
NVO
149.07
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | AXP | NVO |
|---|---|---|
| Current Ratio (MRQ) | 0.71 | 0.78 |
| Quick Ratio (MRQ) | 0.71 | 0.56 |
| Debt-to-Equity Ratio (MRQ) | 6.47 | 0.59 |
| Interest Coverage Ratio (TTM) | 33.37 | 149.07 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
AXP
0.99%
Consumer Finance Industry
- Max
- 8.31%
- Q3
- 3.93%
- Median
- 2.51%
- Q1
- 0.84%
- Min
- 0.00%
AXP’s Dividend Yield of 0.99% is consistent with its peers in the Consumer Finance industry, providing a dividend return that is standard for its sector.
NVO
3.30%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
NVO’s Dividend Yield of 3.30% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
AXP
20.97%
Consumer Finance Industry
- Max
- 145.89%
- Q3
- 88.53%
- Median
- 23.79%
- Q1
- 0.00%
- Min
- 0.00%
AXP’s Dividend Payout Ratio of 20.97% is within the typical range for the Consumer Finance industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
NVO
61.60%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
NVO’s Dividend Payout Ratio of 61.60% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | AXP | NVO |
|---|---|---|
| Dividend Yield (TTM) | 0.99% | 3.30% |
| Dividend Payout Ratio (TTM) | 20.97% | 61.60% |
Valuation
Price-to-Earnings Ratio (TTM)
AXP
21.11
Consumer Finance Industry
- Max
- 34.39
- Q3
- 20.36
- Median
- 13.05
- Q1
- 9.29
- Min
- 4.74
A P/E Ratio of 21.11 places AXP in the upper quartile for the Consumer Finance industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
NVO
13.91
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 13.91 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
AXP
2.86
Consumer Finance Industry
- Max
- 4.28
- Q3
- 2.67
- Median
- 1.88
- Q1
- 1.15
- Min
- 0.55
AXP’s P/S Ratio of 2.86 is in the upper echelon for the Consumer Finance industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
NVO
4.95
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
NVO’s P/S Ratio of 4.95 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
AXP
6.87
Consumer Finance Industry
- Max
- 3.63
- Q3
- 2.40
- Median
- 1.96
- Q1
- 1.16
- Min
- 0.26
At 6.87, AXP’s P/B Ratio is at an extreme premium to the Consumer Finance industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
NVO
8.87
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
NVO’s P/B Ratio of 8.87 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | AXP | NVO |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 21.11 | 13.91 |
| Price-to-Sales Ratio (TTM) | 2.86 | 4.95 |
| Price-to-Book Ratio (MRQ) | 6.87 | 8.87 |
| Price-to-Free Cash Flow Ratio (TTM) | 16.03 | 23.46 |